Items Tagged with 'Pfizer'
The last week of February, a news report said Pfizer reportedly would save $35 billion in taxes by virtue of its announced plans to merge with Allergan. Read More
Sales of Xeljanz will offset losses due to expiring patents such as Lipitor.
The new rheumatoid arthritis drug from Pfizer — Xeljanz — which has just been approved by the Food and Drug Administration, is predicted to yield sales of more than $2 billion a year in a few years. That good news for Pfizer, however, is offset by the fact Pfizer is facing near-term challenges due to expiring patents, resulting in new competition from generic drugs. Read More
NextWave makes the new ADHD drug Quillivant XR.
Global pharmaceutical maker Pfizer has announced its intention to acquire NextWave Pharmaceuticals of Cupertino, Calif., developer of Quillivant XR, the first once-daily liquid medication approved in the U.S. for the treatment of ADHD. Quillivant XR received approval from the U.S. Food and Drug Administration on Sept. 27, and it is expected to be in U.S. pharmacies in January. Read More